

Special Issue

Pain–Neuroinflammation Dyad: New Therapeutic Strategies or Pharmacological Targets to Counter Them

Message from the Guest Editors

Chronic pain persistence can be traced back to a plethora of factors. Very often, the chronicization of pain does not derive from the initial damage progression but rather from central sensitization, where the neuroinflammatory condition plays a key role. Indeed, although the first studies had only focused on investigations at the neuron level, to date, the role of microglia and astrocytes, resulting in the production of cytokines, chemokines, neuropeptides, reactive oxygen species, second messengers, etc., has been slowly uncovered. Despite this, effective treatments, free of side effects, capable of blocking the pain and therefore of interrupting the vicious circle that is established, are currently not yet available. For these reasons, the identification of new targets or therapeutic strategies appears to be of great interest.

This Special Issue will mainly focus on the study of pain, neuroinflammation and related comorbidities, with a particular focus on finding solutions to prevent/slow down/suppress pain, neuroinflammation and related comorbidities. Both original articles and reviews will be considered for inclusion.

Guest Editors

Dr. Giada Amodeo

Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Vanvitelli 32, 20129 Milano, Italy

Dr. Silvia Franchi

Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milano, Italy

Deadline for manuscript submissions

closed (31 August 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/162543

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).